Strike 3: Vical axes its only remaining clinical program, completing a trifecta of disasters
Vical is once again turning to the only tool it evidently knows how to use expertly: the budget ax.
Following back-to-back clinical failures leading up to the summer of 2018, Vical says it has now decided to shelve a Phase II study of the antifungal VL‑2397, citing its desire to conserve cash as it plays out its strategic review. There evidently was also a problem with recruitment for the Phase II, according to the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.